Evolving therapies for the treatment of viral hepatitis

Bibliography

• BEASLEY RP, HWANG LY, LIN CC, et al Hepatocellular Carcinoma and hepatitis B virus: a prospective study of 2707 men in Taiwan. Lancet (1981) 2:1128–1133.
   Web of Science ®Google Scholar
• PERILLO RP, SCHIFF ER, DAVIS GL, et al A randomized, controlled trial of IFN-a-2b alone or after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. New Engl. J. Med. (1990) 323:295–301.
   PubMed Web of Science ®Google Scholar
• •A good paper outlining the role of corticosteroid therapy in the treatment of hepatitis B.
   Google Scholar
• PERILLO RP. Treatment of chronic hepatitis B with IFN: experience in western countries. Semin. Liver Dis. (1989) 9:240–241.
   PubMed Web of Science ®Google Scholar
• ALBERTI A, PONTISSO P, FATTOVICH G, et al Changes in serum hepatitis B virus (HBV) DNA positivity in chronic HBV infection: results of a long-term follow-up study of 138 patients. J. Infect. Dis. (1986) 154:562–569.
   PubMed Web of Science ®Google Scholar
• HINO K, SAINOKAMI S, SHIMODA K, NIWA H, IINO S: Clinical course of acute hepatitis C and changes in HCV markers. Dig. Dis. Sci. (1994) 39:19–27.
   PubMed Web of Science ®Google Scholar
• BARRERA JM, BRUGUERA M, GUADALUPE-ERCILA M, et al Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology (1995) 21:639–644.
   PubMed Web of Science ®Google Scholar
• MCQUILLAN G, ALTER M, MOYER L, LAMBERT S, MARGOLIS H. A population based serologic study of hepatitis C virus infection in the United States. Proceeding of the IX International Symposium on Viral Hepatitis and Liver Disease, Rome (1996) :8A.
   Google Scholar
• TAKAHASHI M, YAMADA G, MIYAMOTO R, et al.: Natural history of chronic hepatitis C. Am. J. Gastoenterol. (1993) 88:240–243.
   PubMed Web of Science ®Google Scholar
• CRANCE JM, BIZIAGOS E, PASSAGOT J, VAN CUYCK-GANDRE H, DELOINCE R. Inhibition of hepatitis A virus replication in vitro by antiviral compounds. J. Med. Virol. (1990) 31:155–160.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS SJ: Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Vir. Hep. Rev. (1995) 1:7–36.
   Google Scholar
• LAU DTY, EVERHART J, KLEINER DE, et al Long term follow-up of patients with chronic hepatitis B treated with IFN-a. Gastroenterology (1997) 113:1660–1667.
   PubMed Web of Science ®Google Scholar
• DAVIS GL, LAU JYN: Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology (1997) 26 (Suppl. 1):1225–1275.
   Google Scholar
• SAIZ-ROYUELA F, PORRES JC, MORENO A, et al High doses of recombinant a-IFN or y-IFN for chronic hepatitis C: a randomized, controlled trial. Hepatology (1991) 13:327–331.
   PubMed Web of Science ®Google Scholar
• BRILLANTI S, MIGLIOLI M, BARBARA L: Combination antiviral therapy with ribavirin and IFN-a in IFN-a relapsers and non-responders: Italian experience. J. Hepatol. (1995) 23:S13–16.
   PubMed Web of Science ®Google Scholar
• SCHVARCZ R, ANDO Y, SONNERBORG A, WEILAND O. Combination treatment with IFN-a-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to IFN alone: Swedish experience. J. Hepatol. (1995) 23 (Suppl. 2) :17–21.
   PubMedGoogle Scholar
• LAI MY, KAO JH, YANG PM, et al Long term efficacy of ribavirin plus IFN-a in the treatment of chronic hepatitis C. Gastroenterology (1996) 111:1307–1312.
   PubMed Web of Science ®Google Scholar
• POYNARD T, LEROY V, COHARD M, et al Meta-analysis of IFN randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology (1996) 24:778–789.
   PubMed Web of Science ®Google Scholar
• AACH RD, STEVENS CE, HOLLINGER FB, et al Hepatitis C virus infection in post transfusion hepatitis. An analysis with first and second generation assays. New Engl. J. Med. (1991) 325:1325–1329.
   PubMed Web of Science ®Google Scholar
• RALL CJN, DIENSTAG JL: Epidemiology of hepatitis C virus infection. Semin Gastointest. Dis (1995) 6:3–12.
   PubMedGoogle Scholar
• SERFATY L, CHAZOUILLIERES O, PAWLOTSKY JM, et al Interferon a therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology (1996) 110:291–295.
   PubMed Web of Science ®Google Scholar
• IDEO G, BELLOBUONO A, TEMPINI S, et al Poor efficacy of a IFN treatment in patients affected by chronic hepatitis C with normal or near normal ALT levels. Gastroenterology (1996) 110:1215A.
   PubMed Web of Science ®Google Scholar
• ORITO E, MIZOKAMI M, SUZUKI K, et al Interferon a therapy for individuals with normal serum alanine aminotransferase levels before treatment. J. Gastroenterol. Hepatol. (1996) 12:58–61.
   Web of Science ®Google Scholar
• WEINER AJ, BRAUER MJ, ROSENBLATT J, et al Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology (1991) 180:842–848.
   PubMed Web of Science ®Google Scholar
• •An important paper describing the genomic variability of hepatitis C.
   Google Scholar
• MATSUMOTO A, TANAKA E, SUZUKI T, OGATA H, KIYOSAWA K: Viral and host factors that contribute to efficacy of IFN-a 2a therapy in patients with chronic hepatitis C. Dig. Dis. Sci. (1994) 39:1273–1280.
   PubMed Web of Science ®Google Scholar
• HAGAIWARA H, HAYASHI N, KASAHARA A, et al Treatment with recombinant IFN-a-2 for patients with chronic hepatitis C: predictive factors for biochemical and virological response. Scand. J. Gastroenterol. (1996) 31:1021–1026.
   PubMed Web of Science ®Google Scholar
• SEEGER C, GANEM D, VARMUS HE: Biochemical and genetic evidence for the hepatitis B virus replication strategy. Science (1986) 232:477.
   PubMed Web of Science ®Google Scholar
• YAP JK, URDEA MS: Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of NS-5 region. J. Gen. Virol. (1993) 74:2391.
   PubMed Web of Science ®Google Scholar
• •An early description of the genotypes of hepatitis C.
   Google Scholar
• BARRERA JM, BRUGUERA M, GUADALUPE - ERCILLA M, et al Persistent hepatitis C viremia after acute self limiting posttransfusion hepatitis C. Hepatology (1995) 21:639–644.
   PubMed Web of Science ®Google Scholar
• ALTER HJ, PURCELL RH, SHIH JVV, et al Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. New Engl. J. Med. (1989) 321:1494–1500.
   PubMed Web of Science ®Google Scholar
• HINO K, SAINOKAMI S, SHIMODA K, NIVVA H, IINO S: Clinical course of acute hepatitis C and changes in HCV markers. Dig. Dis. Sci. (1994) 39:19–27.
   PubMed Web of Science ®Google Scholar
• GISH RG, LAU JY, BROOKS L, et al Ganciclovir treatment of hepatitis B infection in liver transplant recipients. Hepatology (1996) 23:1–7.
   PubMed Web of Science ®Google Scholar
• LAI CL, CHING CK, TUNG ANM, et al Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology (1997) 25:241–244.
   PubMed Web of Science ®Google Scholar
• LAI CL, CHIEN RN, LEUNG NWY, et al A one year trial of lamivudine for chronic hepatitis B. New Engl. J. Med. (1998) 339:61–68.
   PubMed Web of Science ®Google Scholar
• DIENSTAG JL, PERILLO RP, SCHIFF ER, et al A preliminary trial of lamivudine for chronic hepatitis B infection. New Engl. J. Med. (1995) 333:1657–1661.
   PubMed Web of Science ®Google Scholar
• DIENSTAG J, SCHIFF ER, WRIGHT T, et al Lamivudine treatment for one year in previously untreated US hepatitis B patients: histologic improvement and hepatitis B e antigen seroconversion. Gastroenterology (1998) A–1:1.
   Google Scholar
• MAIN J, BROWN JL, KARAYIANNINS P, et al A double-blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J. Virol. Hepat. (1996) 3:211–215.
   PubMed Web of Science ®Google Scholar
• JEFFERS L, HEATHCOTE E, WRIGHT T, et al A Phase II dose-ranging, placebo-controlled trial of adefovir dipivoxil for the treatment of chronic hepatitis B virus infection. Antiviral Res. (1998) 37:A197.
   Google Scholar
• HEATHCOTE J: Lamivudine and Intron A combination treatment in patients with chronic hepatitis B infection. J. Hepatol. (1998) 28: (Suppl. 1) :431A.
   Google Scholar
• YAO F, GISH R: Treatment of Chronic hepatitis B: New Antiviral Therapies. Curr. Gastroent. Op. (1998) In press.
   Google Scholar
• LEUNG YK, SOT: Treatment of chronic hepatitis B using thymosin a 1 and a combination of two nucleoside analogs, lamivudine and famciclovir. Hepatology (1998) 28:A215.
   Google Scholar
• LAU GKK, KWOK A, KARLBERG J, et al A twenty-six week trial of thymosin a-1 plus famciclovir in the treatment of Chinese immune tolerant adult patients with chronic hepatitis B. Hepatology (1998) 28:A216.
   Google Scholar
• SHERMAN KE, SJOGREN M, CREAGER RL, et al Combination Therapy with Thymosin a-1 and IFN for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double blind trial. Hepatology (1998) 27:1128–1135.
   PubMed Web of Science ®Google Scholar
• MARTINOT-PEIGNOUX M, MARCELLIN P, POUTEAU M, et al Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotypes are the main and independent prognostic factors of sustained response to inerferon a therapy in chronic hepatitis C. Hepatology (1995) 22:1050–1056.
   PubMed Web of Science ®Google Scholar
• CHEMELLO L, BONETTI P, CAVALLETTO L, et al Randomized trial comparing three different regimens of a-2a IFN in chronic hepatitis C. Hepatology (1995) 22:700–706.
   PubMed Web of Science ®Google Scholar
• POYNARD R, BEDOSSA P,CHEVALLIER M, et al A comparison of three IFN-a-2b regimens for the long term treatment of chronic non-A, non-B hepatitis. New Engl. J. Med. (1995) 332:1457–1462
   PubMed Web of Science ®Google Scholar
• •An important paper comparing various treatment strategies for hepatitis C.
   Google Scholar
• DIBISCEGLIE A, CONJEEVARAM HS, FRIED MW, et al Ribavirin as therapy for chronic hepatitis C, a randomized, double-blind, placebo-controlled trial. Ann. Int. Med. (1995) 123:897–903.
   PubMed Web of Science ®Google Scholar
• BARTENSCHLAGER R: Molecular targets in inhibition of hepatitis C virus replication. Antiviral Chem. Chemother. (1997) 8:281–302.
   Web of Science ®Google Scholar
• •A comprehensive review of HCV molecular targets.
   Google Scholar
• TAI CL, CHI WK, CHEN DS, et al The helicase activity associated with hepatitis C virus non-structural protein 3(NS3). J. Virol. (1996) 70:8477–8484.
   PubMed Web of Science ®Google Scholar
• KIM JL, MORGENSTERN KA, GRIFFITH JP, et al Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure (1998) 6:89–100.
   PubMed Web of Science ®Google Scholar
• VON WEIZSACKER F, WEILAND S, KOCK J, et al Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants. Hepatology (1996) 26:251–255.
   Google Scholar
• ••An excellent paper outlining the various modalities of genomic targeting.
   Google Scholar
• SAKAMOTO N, WU CH, WU GY: Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. J. Clin. Invest. (1996) 98:2720–2728.
   PubMed Web of Science ®Google Scholar
• •Paper describing how ribozymes work.
   Google Scholar
• ALT M. RENZ R, HOFSCHNEIDER PH, PAUMGARTNER G, CASELMANN WH: Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. Hepatology (1995) 22:707–717.
   PubMed Web of Science ®Google Scholar
• LARREY D. PAGEAUX GP: Hepatotoxicity of herbal remedies and mushrooms. Semin. Liver Dis. (1995) 15:183–201.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of effects of various herbs on the liver.
   Google Scholar
• RIZZETTO M: The delta agent. Hepatology (1983) 3:729–737.
   PubMed Web of Science ®Google Scholar
• SMEDILE A, LAVARINI C, CRIVELLI 0 et al Radioimmunoassay detection of IgM antibodies to HBV associated delta antigen: clinical significance in delta infection. J. Med. Virol (1982) 9:131.
   PubMed Web of Science ®Google Scholar
• SMEDILE A, RIZZETTO M, GERIN JL: Advances in hepatitis D virus biology and disease. Prog. Liver Dis. (1994) 12:157–175.
   PubMedGoogle Scholar
• HU KQ, VIERLING JM: Molecular diagnostic techniques for viral hepatitis. Gastrointest. Clin. North Am. (1994) 23:479–498.
   Google Scholar
• NATH N, FANG CT, BERBERBIAN H, et al Delta antibodies to delta antigen and asymptomatic hepatitis B surface antigen reactive blood donors in the United States and it's association with other markers of hepatitis B virus. Am. J. Epidemiol. (1985) 122:218.
   PubMed Web of Science ®Google Scholar
• GAUDIN JL, FAURE P, GODINOT H, GERARD F, TREPO C: The French experience of treatment of chronic type D hepatitis with a 12-month course of IFN-a-2b. Results of a randomized controlled trial. Liver (1995) 15:45–52.
   PubMedGoogle Scholar
• LAU Y, PARK Y, DOO E, et al Lamivudine treatment of chronic delta hepatitis. Hepatology (1998) 28:A978.
   Web of Science ®Google Scholar
• WONG DC, PURCELL RH, SCREENIVASAN MA, et al Epidemic and endemic hepatitis in India: Evidence for non-A / non-B hepatitis virus etiology. Lancet (1980) 2:876.
   PubMed Web of Science ®Google Scholar
• HERRERA JL: Hepatitis E as a cause of acute non-A, non-B hepatitis. Arch. Intern. Med. (1993) 153:773–775.
   PubMed Web of Science ®Google Scholar
• MISHRA L, SEEFF LB: Viral hepatitis, A through E, complicating pregnancy. Gastroenterol. Clin. North Am. (1992) 21:873–887.
   PubMed Web of Science ®Google Scholar
• •A good description of disease in pregnancy.
   Google Scholar
• MENG XJ, PURCELL RH, HALBUR PG, et al A novel virus in swine is closely related to the human hepatitis E virus. Proc. Natl. Acad. Sci. (1997) 94:9860–9865.
   PubMed Web of Science ®Google Scholar
• TSAREV SA, TSAREVA TS, EMERSON SU, et al Recombinant vaccine against hepatitis E: dose response and protection against heterologous challenge. Vaccine (1997) 15:1834–1838.
   PubMed Web of Science ®Google Scholar
• AMARO MJ: Sequence variability in NS3 region of HGV and HCV during IFN treatment. Hepatology (1998) 28:A810.
   PubMed Web of Science ®Google Scholar
• PETROVA EP, THOMAS MG, WILLIAMS ROGER, NAOUMOV NV. A study on a novel DNA virus (TTV) in liver diseased patients and it's causative role for hepatitis. Hepatology (1998) 28:A816.
   Google Scholar
• OKAMOTO H, NISHIZAWA T, KATO N, et al Molecular cloning and characterization of a novel DNA virus (TTV) associated with posttransfusion hepatitis of unknown etiology. Hepatol. Res. (1998) 10:1–6.
   Web of Science ®Google Scholar
• DINDZANS VJ: Viral hepatitis. Preexposure and postexposure prophylaxis. Postgrad. Med. (1992) 92:43–52.
   PubMed Web of Science ®Google Scholar
• •A good reference and guide for vaccination.
   Google Scholar
• MA DDF, DOAN TL: Antisense oligonucleotide therapies: are they the 'magic bullets' Ann. Int. Med. (1994) 120:161–163.
   Web of Science ®Google Scholar
• FATTOVICH G, GUISTINA G, FAVARATO S, et al A survey with adverse events in 11,241 patients with chronic viral hepatitis treated with a IFN. J. Hepatol. (1996) 24:38–47.
   PubMed Web of Science ®Google Scholar
• •An excellent review of IFN side-effects.
   Google Scholar
• FLAHERY J, LALEZARI J, PETTY B, et al Pharmocokinetics and safety of oral lobucavir in cytomegalovirus-infected HIV patients (protocol AI459-005). 4th Conference on Retro viruses and Opportunistic Infections. Washington DC, USA (1997):301.
   Google Scholar